Roche presented new data at ECTRIMS 2025 confirming that OCREVUS provides sustained protection against disability progression and maintains a con ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback